Comparative outcomes of opioid withdrawal management strategy in patients with injection-related bacteremia
Authors:
- 15 June 2026
- journal article
- Published by Taylor & Francis in Journal of Addictive Diseases
- p. 1-8
Abstract
Hospitalized patients with opioid use disorder present unique clinical challenges, including higher rates of patient-directed discharge (PDD), incomplete treatment courses, and frequent readmissions. To compare outcomes in hospitalized patient encounters involving OUD and bacteremia that were ordered medications for opioid use disorder versus high-dose opioid agonist therapy (HDOAT) alone. This single-center, retrospective study included 268 OUD patients, 383 encounters, and 303 cases of bacteremia admitted to Temple University Hospital from Jan 1, 2020 through Dec 31, 2022. Outcomes of interest included PDD, 7 and 30-day readmission, inpatient mortality, length of stay (LOS), one year mortality and antibiotic completion. Bacteremia is a serious illness and requires long term treatment, thus it is an optimal model for this work. Of 383 encounters, 234 involved MOUD, and 149 involved HDOAT alone. Among the HDOAT group, doses were up to 2,070 MMEs/day. MOUD included buprenorphine and methadone. HDOAT included non-MOUD full agonist such as oxycodone and/or hydromorphone. For case-level outcomes, MOUD was associated with higher antibiotic completion (35.0% vs 23.3%, OR 1.77, p < 0.05). For encounter-level outcomes, MOUD was associated with lower PDD rates (38.5% vs 69.8%, OR 0.27, p < 0.0001) and longer LOS (8d vs 3d), seven-days readmission and inpatient mortality rates were similar between groups. However, 30-day readmission rate was lower in the MOUD group (32.9% vs 43.0%, OR 0.65, p < 0.05). PDD, readmission and mortality were similar regardless of timing of MOUD initiation ( 72h) or severity of opioid dependence. Notably, 23% of HDOAT cases successfully completed antibiotics, often across multiple encounters. MOUD initiation was associated with lower PDD and higher antibiotic completion rates. Timing of MOUD initiation did not affect outcomes. HDOAT may serve as a second-line approach to support continuity of care in patients declining MOUD.Keywords
This publication has 15 references indexed in Scilit:
- Initiating Injectable Buprenorphine in People Hospitalized With InfectionsJAMA Network Open, 2025
- Addiction Consultation Services for Opioid Use Disorder Treatment Initiation and EngagementJAMA Internal Medicine, 2024
- Medication for Opioid Use Disorder After Serious Injection-Related Infections in MassachusettsJAMA Network Open, 2024
- Quantitative Analysis of Characteristics Associated with Patient-Directed Discharges, Representations, and Readmissions: a Safety-Net Hospital ExperienceJournal of General Internal Medicine, 2023
- Use of Medication for Opioid Use Disorder Among Adults With Past-Year Opioid Use Disorder in the US, 2021JAMA Network Open, 2023
- The risk factors, consequences, and interventions of discharge against medical advice - A narrative reviewThe American Journal of the Medical Sciences, 2023
- Infectious Complications of Injection Drug UseMedical Clinics of North America, 2022
- Association Between Medicaid Expansion and Rates of Opioid-Related Hospital UseJAMA Internal Medicine, 2020
- Comparative Effectiveness of Different Treatment Pathways for Opioid Use DisorderJAMA Network Open, 2020
- Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid DetoxificationJournal of Substance Abuse Treatment, 2016